Accelerated approval is a regulatory pathway designed by the FDA to expedite the availability of treatments for serious conditions where there is an unmet medical need. This mechanism allows for earlier approval of drugs based on surrogate endpoints that are reasonably likely to predict clinical benefit, rather than waiting for direct evidence of clinical benefit.
